RSQ-006 - Comparison of treatment effects between ACR response criteria and target-based outcomes for contemporary rheumatoid arthritis drug approval trials: A meta-epidemiological study

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: RSQ-006
• By: DONG, Wenliang (Peking University, China)
• Co-author(s): Dr Wenliang Dong (Peking University, Beijing, China)
  Dr Gengchen Wang (Peking University, Beijing, China)
  Dr Xiaowen Hu (Peking University, Beijing, China)
  Prof Xiaoyan Nie (Peking University, Beijing, China)
  Prof Luwen Shi (Peking University, Beijing, China)
  
• Abstract:

  Introduction:
  Regulatory priorities diverge between agencies - the FDA maintained ACR20 response as primary endpoint in rheumatoid arthritis (RA) trials, whereas the EMA emphasized target-based outcomes centered on remission and low disease activity (LDA). To systematically compare treatment effect estimates between American College of..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login